Repare Therapeutics Stock Operating Margin

RPTX Stock

USD 2.81 0.16 5.39%

Repare Therapeutics fundamentals help investors to digest information that contributes to Repare Therapeutics' financial success or failures. It also enables traders to predict the movement of Repare Stock. The fundamental analysis module provides a way to measure Repare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Repare Therapeutics stock.

		Last Reported	Projected for Next Year
	Operating Profit Margin	(2.27)	(2.39)

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Repare Therapeutics Company Operating Margin Analysis

Repare Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current Repare Therapeutics Operating Margin

(1.39) %

Most of Repare Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repare Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Repare Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Repare Therapeutics is extremely important. It helps to project a fair market value of Repare Stock properly, considering its historical fundamentals such as Operating Margin. Since Repare Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Repare Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Repare Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Short Term Investments
Total Assets		0.98	0.95	-0.91	-0.82	0.47	0.61	0.86	0.49	0.98	1.0	0.96	0.99	0.96	0.9	0.65	0.83	0.6
Total Stockholder Equity	0.98		0.98	-0.88	-0.82	0.42	0.61	0.84	0.31	1.0	0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Net Tangible Assets	0.95	0.98		-0.83	-0.86	0.47	0.67	0.87	0.26	0.98	0.95	0.99	0.94	0.99	0.94	0.6	0.89	0.64
Net Debt	-0.91	-0.88	-0.83		0.56	-0.6	-0.37	-0.62	-0.51	-0.88	-0.91	-0.81	-0.94	-0.81	-0.7	-0.34	-0.57	-0.22
Retained Earnings	-0.82	-0.82	-0.86	0.56		-0.45	-0.89	-0.99	-0.27	-0.82	-0.81	-0.9	-0.78	-0.9	-0.87	-0.64	-0.96	-0.77
Accounts Payable	0.47	0.42	0.47	-0.6	-0.45		0.58	0.44	0.39	0.42	0.46	0.44	0.52	0.44	0.44	-0.29	0.31	-0.14
Net Receivables	0.61	0.61	0.67	-0.37	-0.89	0.58		0.82	0.16	0.61	0.61	0.69	0.6	0.69	0.76	0.33	0.75	0.59
Capital Surpluse	0.86	0.84	0.87	-0.62	-0.99	0.44	0.82		0.34	0.84	0.85	0.91	0.82	0.91	0.85	0.68	0.96	0.75
Total Liab	0.49	0.31	0.26	-0.51	-0.27	0.39	0.16	0.34		0.31	0.49	0.31	0.5	0.31	0.36	0.31	0.24	0.2
Net Invested Capital	0.98	1.0	0.98	-0.88	-0.82	0.42	0.61	0.84	0.31		0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Total Current Assets	1.0	0.98	0.95	-0.91	-0.81	0.46	0.61	0.85	0.49	0.98		0.96	0.99	0.96	0.9	0.65	0.83	0.61
Capital Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96		0.94	1.0	0.94	0.66	0.93	0.69
Net Working Capital	0.99	0.97	0.94	-0.94	-0.78	0.52	0.6	0.82	0.5	0.97	0.99	0.94		0.94	0.88	0.57	0.78	0.53
Common Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96	1.0	0.94		0.94	0.66	0.93	0.69
Property Plant Equipment	0.9	0.9	0.94	-0.7	-0.87	0.44	0.76	0.85	0.36	0.9	0.9	0.94	0.88	0.94		0.64	0.89	0.76
Current Deferred Revenue	0.65	0.63	0.6	-0.34	-0.64	-0.29	0.33	0.68	0.31	0.63	0.65	0.66	0.57	0.66	0.64		0.74	0.91
Short Term Debt	0.83	0.84	0.89	-0.57	-0.96	0.31	0.75	0.96	0.24	0.84	0.83	0.93	0.78	0.93	0.89	0.74		0.83
Short Term Investments	0.6	0.61	0.64	-0.22	-0.77	-0.14	0.59	0.75	0.2	0.61	0.61	0.69	0.53	0.69	0.76	0.91	0.83

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict Repare Therapeutics

Operating Profit Margin Over Time

Repare Pretax Profit Margin

Pretax Profit Margin

(2.12)

At this time, Repare Therapeutics' Pretax Profit Margin is fairly stable compared to the past year.

Based on the recorded statements, Repare Therapeutics has an Operating Margin of -1.3862%. This is 96.05% lower than that of the Biotechnology sector and 98.76% lower than that of the Health Care industry. The operating margin for all United States stocks is 74.84% lower than that of the firm.

Repare Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Repare Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Repare Therapeutics could also be used in its relative valuation, which is a method of valuing Repare Therapeutics by comparing valuation metrics of similar companies.

Repare Therapeutics is currently under evaluation in operating margin category among its peers.

Repare Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repare Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repare Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Repare Fundamentals

	Return On Equity	-0.41
	Return On Asset	-0.23
	Profit Margin	(1.26) %
	Operating Margin	(1.39) %
	Current Valuation	(57.41 M)
	Shares Outstanding	42.51 M
	Shares Owned By Insiders	0.95 %
	Shares Owned By Institutions	83.62 %
	Number Of Shares Shorted	749.74 K
	Price To Book	0.68 X
	Price To Sales	1.80 X
	Revenue	51.13 M
	Gross Profit	15.11 M
	EBITDA	(114.27 M)
	Net Income	(93.8 M)
	Cash And Equivalents	282.09 M
	Cash Per Share	6.73 X
	Total Debt	3.41 M
	Debt To Equity	0.03 %
	Current Ratio	7.35 X
	Book Value Per Share	4.12 X
	Cash Flow From Operations	(127.16 M)
	Short Ratio	6.38 X
	Earnings Per Share	(1.99) X
	Target Price	12.5
	Number Of Employees	179
	Beta	0.71
	Market Capitalization	119.46 M
	Total Asset	253.9 M
	Retained Earnings	(333.11 M)
	Working Capital	204.61 M
	Net Asset	253.9 M

About Repare Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Repare Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC